In collaboration with its strategical research partner, Shanghai Jiao Tong University, Pulse Medical pioneered in development of innovative techniques for assessment of computational physiology and plaque vulnerability, including angiography-based Murray-law quantitative flow ratio (μFR®), CTA-based Murray-law quantitative flow ratio (CT-μFR), optical flow ratio (OFR), ultrasonic flow ratio (UFR), and radial wall strain (RWS). These novel techniques have been widely used in clinical routine for identification of flow-limiting coronary stenosis and for making optimal treatment strategy.
One of these innovative projects “Real-time comprehensive assessment of coronary physiology and biomechanics from a single angiographic projection” was granted the Best Innovation Award and the Jon DeHaan Foundation Grant at the EuroPCR congress in 2022. The key concept has been implemented in the AngioPlus Core software and was granted as Breakthrough Device by FDA.
Ourmission is to develop and deliver the innovative value-based solutions toimprove patient outcomes.